Atrasentan Associated With Lower Risk for Kidney Events in T2D With CKD
Atrasentan is associated with a reduced risk for renal events in patients with type 2 diabetes and chronic kidney disease.
Type 2 Diabetes
Evolocumab Effective, Well Tolerated in Patients With Type 2 Diabetes Receiving Statin Therapy
The addition of monthly evolocumab to statin therapy for individuals with hypercholesterolemia or mixed dyslipidemia and type 2 diabetes led to significant reductions in low-density lipoprotein cholesterol.
ADA Updates Consensus Report Regarding Personalized Nutrition Therapy in Type 2 Diabetes
There is no single recommended nutrition plan for all people with diabetes given the broad spectrum of people affected by diabetes and prediabetes.
Younger Age at Type 2 Diabetes Diagnosis Associated With Higher Risk for CVD, Mortality
Being a younger age at diagnosis of type 2 diabetes is associated with greater risk for total mortality and mortality related to cardiovascular disease outcomes.
Rate of Gastric Emptying Elevated in Well-Controlled Type 2 Diabetes
Participants with relatively well-controlled type 2 diabetes experience an increased rate of gastric emptying compared with healthy controls.
Metformin Use and Vitamin B12 Deficiency: Managing the Risks
With the direct correlation between metformin use and vitamin B12 deficiency established, implementation of guidelines for B12 screening should be considered.
Evolocumab Is Safe, Effective as Statin Add-On in Type 2 Diabetes
Investigators examined the safety and lipid‐lowering efficacy of evolocumab combined with atorvastatin in patients with type 2 diabetes and hyperlipidemia or mixed dyslipidemia.
Improvements in Insulin Resistance With Semaglutide Primarily a Result of Weight Loss
Reductions in insulin resistance with semaglutide vs comparators are primarily mediated by semaglutide’s effect on body weight.
Canagliflozin Lowers ESRD Risk in T2D With Chronic Kidney Disease
In a study of patients with type 2 diabetes and chronic kidney disease, canagliflozin, an SGLT2 inhibitor, decreased the risk of end-stage renal disease by 32% compared with placebo.
Metformin Use, B Vitamin Deficiency Linked to Reduced Cognitive Performance
Investigators sought to establish the effect of hyperglycemia and metformin use on relevant B-vitamin biomarkers and cognitive outcomes in older adults.
Next post in Type 2 Diabetes
